ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Biotech Shorts Hit 135%

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

PSTV Plus Therapeutics exploded to 135% short interest this week. The biotech jumped 125 points in seven days as bears piled in. The $9M firm held just 11% SI last Wednesday showing dramatic position building.

HCTI Healthcare Triangle grabbed 121% SI up 53 points weekly. Cost to borrow hit 244% while availability collapsed to 7%. The health tech name absorbed relentless selling pressure despite microscopic $2.7M market cap.

GNLN Greenlane reached 88% SI after whipsawing between 6% and 89% in four trading days. The cannabis accessory retailer saw wild swings suggesting technical repositioning. Bears added 40 points in seven days.

QNCX Quince Therapeutics climbed to 54% SI adding 34 points weekly. The $61M neurology biotech drew concentrated shorting as broader healthcare names faced pressure. Target upside exceeded 260% per analyst consensus.

PMAX Powell Max topped all names at 63,169% SI demonstrating extreme statistical distortion. Cost to borrow reached 447% making new positions prohibitively expensive. The $3.8M capital markets firm held minimal float creating technical anomaly.

AGL Agilon Health held 212% SI as the largest shorted healthcare stock by size. The $275M provider faced 73 short score with 4.1 days to cover. Analyst upside sat at just 0.4% showing bear conviction.

Biotech shorting accelerated amid defensive rotation out of speculative healthcare.

How this article was generated

Generated
10 Apr 2026, 20:04
Prompt version
migrated
Data sources
Short interestCost to borrowUtilizationAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.